
|Videos|June 2, 2015
Adding Palbociclib Delays Progression in HR-Positive Breast Cancer
Author(s)Nicholas C. Turner, MD
In this video we discuss the results of the PALOMA3 trial, which tested fulvestrant and palbociclib in metastatic, hormone receptor–positive HER2-negative breast cancer.
Advertisement
In this video, Nicholas C. Turner, MD, of Royal Marsden Hospital and the Cancer Research Institute in London, discusses the results of the PALOMA3 trial, which tested fulvestrant and palbociclib in metastatic, hormone receptor (HR)-positive HER2-negative breast cancer.
Newsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on CancerNetwork
1
What to Consider After Diagnosing a Patient with Ductal Carcinoma in Situ?
2
FDA Grants RMAT Designation to HSV-Based Immunotherapy in NSCLC
3
Frontline Multiple Myeloma Therapy: Kicking the Can Further Down the Road?
4
FDA Grants Orphan Drug Designation to Zenocutuzumab in Cholangiocarcinoma
5






































